Getinge AGM Backs Dividend, Board Lineup and Share Buyback Mandate

An announcement from Getinge ( ($SE:GETI.B) ) is now available.

Getinge’s annual general meeting approved the 2025 financial statements, re-elected most of the board and its chairman, and added Camilla Sylvest as a new director, while also confirming employee-appointed board representatives. Shareholders backed a dividend of SEK 4.75 per share, set detailed board and committee remuneration levels, reappointed Ernst & Young as auditor, endorsed executive pay guidelines and the remuneration report, and authorized the board to repurchase up to 10% of the company’s Class B shares, providing flexibility for future capital management and signaling continued confidence in its financial position.

The resolutions on board composition and fee structures support continuity in Getinge’s governance and oversight at a time when stability is important for global medtech players. The share buyback authorization adds a tool to adjust the capital structure and potentially enhance shareholder returns, while the maintained auditor mandate and approved pay policies are intended to reinforce transparency and align management incentives with shareholder interests.

The most recent analyst rating on ($SE:GETI.B) stock is a Hold with a SEK235.00 price target. To see the full list of analyst forecasts on Getinge stock, see the SE:GETI.B Stock Forecast page.

More about Getinge

Getinge is a global medical technology company that supplies hospitals and life science institutions with products and solutions designed to improve clinical outcomes and streamline workflows. Its portfolio spans intensive care, cardiovascular procedures, operating rooms, sterile reprocessing and life science applications, and it employs about 12,000 people serving customers in more than 135 countries worldwide.

Average Trading Volume: 712,110

Technical Sentiment Signal: Hold

Current Market Cap: SEK54.38B

For a thorough assessment of GETI.B stock, go to TipRanks’ Stock Analysis page.